HLS Therapeutics Inc (TSX:HLS)
C$ 3.5 0.09 (2.64%) Market Cap: 111.28 Mil Enterprise Value: 183.69 Mil PE Ratio: 0 PB Ratio: 1.04 GF Score: 66/100

Q2 2022 HLS Therapeutics Inc Earnings Call Transcript

Aug 11, 2022 / 12:30PM GMT
Release Date Price: C$12.99 (-1.37%)
Operator

Good morning, and welcome to the Q2 Fiscal 2020 Financial Results Conference Call for HLS Therapeutics. On this morning's call we have Gilbert Godin, Chief Executive Officer; and Tim Hendrickson, Chief Financial Officer.

Earlier this morning, HLS issued a news release announcing financial results for the 3 and 6-month periods ending June 30, 2022. This news release along with the company's MD&A and financial statements will be available on HLS' website and on SEDAR. Please note that slides accompanying today's call can be viewed via the webcast, a link on which is available in the company's earnings press release and at its website on the Events page.

Certain matters discussed in today's conference call or answers that may be given to questions could constitute forward-looking statements. Actual results could differ materially from those anticipated. Risk factors that could affect results are detailed in the company's annual information form which has been filed on SEDAR at www.sedar.com. During this conference call HLS

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot